Congressional spending plan: What’s in it for healthcare, and what isn’t
Chief Healthcare Executive December 21, 2024
The Trump Sequel: What to Expect on PBMs, 340B, Drug Pricing, and RFK Jr
AJMC November 12, 2024
Key Takeaways
- The $2000 Medicare Part D out-of-pocket cap is likely to remain, despite its high cost to the federal government.
- Potential changes to the IRA’s price negotiation features could occur, especially with a Republican-controlled Congress.
- The Most Favored Nation policy for drug pricing may be revisited, though its future remains uncertain.
- 340B program reforms and PBM reforms are likely priorities, with bipartisan support for transparency and compensation delinking.
- RFK Jr. may play a significant advisory role in health policy, potentially influencing drug policy and public health initiatives.
Lindsay Bealor Greenleaf, JD, MBA, of ADVI Health, weighs in on what to expect in key health care policy areas in the wake of the election.
Last week’s election results...
Today's Sponsors
Today's Sponsor